Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 and Pembrolizumab in BCG-Unresponsive NMIBC
NCT05843448Phase 1Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- Apr 2023
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PD-L1/IDO peptide vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by University of California, Davis. Primary endpoint: Incidence of adverse events. Started Apr 2023; status: active, not recruiting.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05843448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843448.